There are several causes for this rise in interest. The U.S. government has contributed through 3 recent events, the 1992 NIH consensus development conference on impotence,1 the 1993 international conference on Peyronie's disease and the 1995 FDA approval of prostaglandin E-1 for intracavernous injections. The New York Male Reproductive Center performs clinical research studies on new investigational treatments of sexual dysfunction all the time. Patients interested in participating in clinical research studies are usually seen in an initial office consultation to determine their eligibility for a particular study and to inform them about the details of the proposed research. Eligible candidates may join studies that are open to enrollment.
Participation is completely voluntary.
It is important to understand that at a particular time some of the ongoing studies will be open for enrollment and others may have been closed for new enrollment after satisfying the permitted number of patients. This situation is subject to change all the time. The following is general information about the clinical trials at our Center. This is a the second study performed on this approach for the treatment of organic erectile dysfunction. The medication exerts its effect through the dopamine receptors in the brain.